ARQ-252 cream 0.3%

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial VitiligoNCT04811131ARQTPhase 2Terminated2021-08-09Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.